Good morning, everybody, and welcome to the center of the week. Congratulations on making it this far, and keep in…
Read More
We’re studying about new Novo CEO, FDA reversal on Sarepta
Rise and shine, one other busy — and steamy — day is on the way in which. We will inform…
Read MoreWe’re studying about FDA ‘skilled panels,’ knock-off weight problems medicine
Good morning, everybody, and good to see you once more after we took a little bit of day without work…
Read MoreWe’re studying about Roche revenue, direct-to-patient drug gross sales
Thursday greetings to you all, with Andrew Joseph right here in London filling in for Mr. Pharmalot. Our cups of…
Read MoreWe’re studying about Sarepta’s path, pharma reliance on China
Good afternoon from STAT’s London outpost, with Andrew Joseph right here on rotation for the vacationing Mr. Pharmalot. We’re on…
Read MoreWe’re studying about Sarepta conceding to FDA, transplant system
Good morning everybody, it’s Jason Mast, filling in for Ed once more. Right here’s a enjoyable truth about medication, pulled…
Read MoreWe’re studying about Bristol-Pfizer DTC gross sales plan, Sarepta layoffs
Rise and shine, everybody, one other busy day is on the way in which. We are able to inform by…
Read MoreWe’re studying about Trump and pharma tariffs, abortion tablet ruling
Howdy, everybody, and the way are you right now? We’re doing simply high quality, thanks, particularly for the reason that…
Read MoreWe’re studying about FDA person charges, rising GLP-1 use by kids
Rise and shine, one other busy day is on the way in which. And will probably be a steamy one,…
Read MoreWe’re studying about GLP-1 medicine for habit, FDA funding
Good morning, everybody, and welcome to a different working week. We hope the weekend respite was enjoyable and invigorating, as…
Read More
